



GIG
CYMRU
NHS
WALES

Bwrdd Iechyd Prifysgol
Cwm Taf Morgannwg
University Health Board



Freedom of Information Request: Our Reference CTMUHB_62_25

You asked:

I am analysing the usage of new biologic and targeted medications. Could you please answer the following question:

Q1. How many patients were treated in January 2025 (or latest available month) by the Dermatology department with the following drugs:

- Abrocitinib (Cibinqo)
- Baricitinib (Olmiant)
- Dupilumab (Dupixent)
- Lebrikizumab (Ebglyss)
- Omalizumab (Xolair)
- Tralokinumab (Adtralza)
- Upadacitinib (Rinvoq)

Q2. How many patients were treated in January 2025 (or latest available month) by the Respiratory Medicine departments with the following drugs:

- Benralizumab (Fasenra)
- Dupilumab (Dupixent)
- Mepolizumab (Nucala)
- Omalizumab (Xolair)
- Reslizumab (Cinqaero)
- Tezepelumab (Tezspire)

Our response:

In response to your recent enquiry above please find below tables populated with the information Medicines Management are able to provide at this current time. The period the data relates to is January 25 the latest month available.

Q1.

Medicine	Number of Patients
Abrocitinib (Cibinqo)	**
Baricitinib (Olmiant)	0
Dupilumab (Dupixent)	115
Lebrikizumab (Ebglyss)	5
Omalizumab (Xolair)	23
Tralokinumab (Adtralza)	13
Upadacitinib (Rinvoq)	7

Q2.

Medicine	Number of Patients
Benralizumab (Fasenra)	18
Dupilumab (Dupixent)	**
Mepolizumab (Nucala)	54
Omalizumab (Xolair)	23
Reslizumab (Cinqaero)	0
Tezepelumab (Tezspire)	20

Where the figures are less than 5, this has been denoted by **.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain.

In our view disclosure of these low figures would breach the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR.

We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.